Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 15/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 15/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506011 | 0.87 | SIRT6 (0.57) | NR1H3NR1H2SIRT6ALDH1A1LMNA | |
| SCHEMBL3506016 | 0.87 | SIRT6 (0.57) | NR1H3NR1H2SIRT6ALDH1A1LMNA | |
| SCHEMBL4573483 | 0.87 | NR1H3 (0.66) | NR1H3NR1H2 | |
| SCHEMBL4573487 | 0.87 | NR1H3 (0.66) | NR1H3NR1H2 | |
| SCHEMBL310369 | 0.81 | MAPT (0.65) | SIRT6ALDH1A1LMNAMAPT | |
| SCHEMBL29802982 | 0.81 | MAPT (0.65) | SIRT6ALDH1A1LMNAMAPT | |
| SCHEMBL25370804 | 0.79 | SIRT6 (0.56) | SIRT6ALDH1A1LMNAMAPT | |
| SCHEMBL13163392 | 0.78 | NR1H3 (0.54) | NR1H3NR1H2 | |
| SCHEMBL3503419 | 0.77 | SIRT6 (0.57) | SIRT6ALDH1A1LMNAMAPT | |
| SCHEMBL28795348 | 0.77 | ALDH1A1 (0.53) | SIRT6ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093239-B2 | Imidazopyridine kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2010-08-26 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300242-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | NR1H3 4331/4885NR1H2 4382/4885SIRT6 1497/4885 |
| US-20100216779-A1 | Imidazopyridine Kinase Inhibitors | ABL1, MAP3K19, MAP3K5 | NR1H3 4331/4885NR1H2 4382/4885SIRT6 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.